Steady-state plasma levels during antidepressant therapy with amitriptyline and amitriptylinoxide

Area of Science:

• Pharmacology
• Clinical Chemistry
• Psychiatry

Background:

• Tricyclic antidepressants (TCAs) like amitriptyline are widely used for depression.
• Understanding the pharmacokinetics and metabolism of TCAs is crucial for optimizing therapy.
• Amitriptyline and amitriptylinoxide represent different formulations/metabolic pathways of a common TCA.

Purpose of the Study:

• To compare plasma concentrations and metabolite profiles of amitriptyline and amitriptylinoxide.
• To evaluate the therapeutic efficacy and pharmacokinetic parameters of both drugs.
• To assess the utility of a kinetic model for predicting metabolite levels in TCA therapy.

Main Methods:

• Controlled clinical trial involving two groups of depressed patients.
• Analysis of plasma levels of amitriptyline, amitriptylinoxide, and their metabolites.
• Calculation of total clearance and application of a first-order kinetic model for metabolite prediction.
• High-Performance Liquid Chromatography (HPLC) used for metabolite quantification.

Main Results:

• Demethylated and hydroxylated derivatives were the primary metabolites for both drugs.
• Amitriptylinoxide was significantly reduced to amitriptyline in vivo.
• Continuous oral administration (150 mg/day) achieved therapeutic concentrations for both drugs.
• Plasma concentrations were 2-3 times higher with amitriptyline compared to amitriptyline oxide.
• Calculated total clearance of amitriptyline was 7 ml/min/kg.
• Predicted and HPLC-determined nortriptyline levels showed good agreement for both drug regimens.

Conclusions:

• Both amitriptyline and amitriptylinoxide achieve therapeutic plasma concentrations.
• Amitriptyline exhibits higher plasma levels and faster clearance, potentially offering more predictable therapeutic drug monitoring.
• The proposed kinetic model demonstrates practical utility for estimating steady-state concentrations of TCA metabolites.
• Further research can refine this model for routine clinical application in managing TCA therapy.